目前腫瘤血管靶向治療新藥的研究主要集中在兩個方向，即腫瘤血管生成抑制劑（tumor angiogenesis inhibitor，TAI）和腫瘤血管靶向制劑（vascular targeting agent，VTA）。TAI類旨在抑制腫瘤血管生成的過程，近年來研究較多的為血管內(nèi)皮生長因子（VEGF）類、基質(zhì)金屬蛋白酶（MMP）類、血管抑素類、內(nèi)皮抑素類等；而VAT類則是通過破壞腫瘤組織中已存在的血管從而使腫瘤壞死，主要包括小分子類VTA和生物類VTA。對近年來各類抗腫瘤血管治療新藥的種類、作用機制及各自的臨床研究進展進行綜述。

Nowadays two aspects were involved in research on new drugs of tumor vascular targeting therapy, including tumor angiogenesis inhibitor (TAI) and vascular targeting agent (VTA). TAI aimed to inhibit the process of new angiogenesis and the most studied TAI agents were VEGF TAI, MMP TAI, angiostatin, endostatin and so on. The VTA induced a tumor necrosis through destroying vessels in tumor tissue, mainly including small molecularVTA and biological VTA. This review summarizes the types of anti-angiogenesis drug, their molecule mechanisms and the clinical research progress.